Sanaria
biotech company based in Rockville, Maryland, United States
Sanaria is a biotechnology company founded to develop whole-parasite vaccines protective against malaria. Sanaria is also developing monoclonal antibodies protective against malaria, vaccines against diarrheal diseases, immunotherapeutics for disease of the liver, and related products for us in malaria research. Sanaria's vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a carrier for immunomodulatory molecules.
Mission statement
Sanaria's primary mission is to develop and commercialize whole-parasite PfSPZ vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the malaria parasite responsible for more than 95% of malaria-associated severe illness and death worldwide and the malaria parasite for which there is the most significant drug resistance. The long-term goal is to develop vaccines that prevent all human malaria and use these vaccines to immunize entire populations in geographically defined areas to halt malaria transmission and eliminate malaria. This will be accomplished by first introducing vaccines to prevent malaria in specific populations like pregnant women and children in malaria endemic areas, as well as travelers to malaria endemic areas.
History
Sanaria moved into its first facility in Rockville, MD in July 2003 supported by a phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) and subsequently by a $4.09M grant from the United States Army Medical Research Acquisition Activity Group to further develop its vaccine. In 2007, Sanaria received a $29.3-million grant from the Bill and Melinda Gates Foundation (BMGF), administered through the PATH Malaria Vaccine Initiative (MVI) which supported the construction of Sanaria's manufacturing facility in Rockville, MD. In 2009, Sanaria received approval from the FDA to test PfSPZ Vaccine in human trials. Sanaria® PfSPZ Vaccine is highly protective against Pf malaria transmitted by controlled human malaria infection (CHMI) and naturally transmitted Pf malaria in Africa for ywo years without intervening booster doses, including during pregnancy. PfSPZ Vaccine received FDA Fast Track Designation in 2016.
This brief starts where responsible research should: with the source description of “Sanaria” as biotech company based in Rockville, Maryland, United States. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the history & society register because the source frames it as biotech company based in Rockville, Maryland, United States. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Contemporary correspondence, administrative files and participant testimony can test how later narratives organized the event or institution. The source revision retrieved here is dated Aug 18, 2026. The linked authority identifier is Q22032316. 2 of 2 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 2003, 2007, 2009 and 2016.
Institutional narratives can privilege the records that survived while minimizing voices that were never formally collected. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Sanaria”, its source revision and the description used here.
- Expand the search: follow Sanaria primary sources, Sanaria archive and Sanaria research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Sanaria”?
- Which voices are present, absent or mediated by the institution?
- Who created the surviving record, and for what administrative purpose?
Search terms from this dossier
This entry incorporates text from “Sanaria” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.